According to recent research, many recreational cannabis users use the plant instead of sleeping pills. Cannabis is proven to help people fall asleep. Researchers used data from a grocery store and based on it measured monthly sales of sleeping pills by location. With the opening of legal cannabis stores, sales of over-the-counter sleeping pills in nearby grocery stores decreased.
Insomnia is not a condition that qualifies for medical cannabis use in any state in America, but recent research suggests that many recreational cannabis users are using cannabis for sleep.
Medical cannabis is a sector that brings profit in the cannabis industry. One potentially useful cannabis news tool is Hemp.im app and its companion marijuana news website.
Hemp.im provides the latest news about the CBD and hemp sector, which is predicted to be worth more than $14.67 billion by 2026.
According to new research, people with insomnia can use cannabis to help them fall asleep instead of using traditional OTC sleeping pills.
The study, recently published in the journal, “Complementary Therapies in Medicine,” aims to explain “whether people are replacing recreational cannabis with conventional over-the-counter sleeping pills.”
To test their theory, researchers have studied data from a grocery store scanner registered in Colorado, between December 2013 and December 2014. Based on this data, the researchers measured monthly sales of sleeping pills at different locations.
In 2014, adult cannabis sales became legal in Colorado, and licensed cannabis shops began to gradually appear. Researchers monitored every cannabis store that opened and observed whether sales of sleeping pills decreased in local grocery stores.
“Compared to the general market for sleeping pills, the market share of over-the-counter sleeping pills was increasing before recreational cannabis was available,” wrote the authors of the study.
But after the opening of legal cannabis stores, sales of over-the-counter sleeping pills in nearby grocery stores have fallen.
As the number of cannabis stores in the same district increased, so did the sales of cannabis. This ultimately resulted in a further decline in the share of OTC sleeping pills in the overall sleeping pills market.
The study shows that sales of drugs such as diphenhydramine (Benadryl) and doxylamine (Unisom) have fallen significantly more than sales of natural sleeping aids such as melatonin.
“These facts confirm the results of a survey showing that many people use cannabis to treat insomnia, although sleep disturbances are not on the list that qualifies for a prescription for medical cannabis,” The authors summed it up. “Research to measure the relative efficacy and side-effect profiles of conventional OTC and cannabis-based sleeping pills is urgently needed to improve the treatment of sleep disorders while minimizing potentially serious adverse side effects.”
“We see declining sales of OTC sleeping pills that can be associated with direct users of cannabis to treat sleep disorders, because cannabis affects basic conditions and behaviors affecting sleep, such as anxiety,” said Sarah Stith, co-author of the study, Assistant Professor at the University of New Mexico (UNM), in a statement. “Our earlier research confirms the existence of both mechanisms.”
The Federal ban on cannabis, which prevents many scientists from legally obtaining high-quality cannabis for clinical trials, has forced scientists to use this method to test their hypothesis.
__
(Featured image by Alessandro Zambon via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FaktyKonopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…
The European Commission has launched an investigation into Italy after its recent proposal to ban…
A new study has found that prolonged use of high-THC cannabis leaves a unique mark…